Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 80

Sort by

Sort Order Select

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Meghan C. Thompson, Ricardo D. Parrondo, Anna Maria Frustaci, John N. Allan, Paolo Ghia, Irina Mocanu, Constantine S. Tam, Judith Trotman, Inhye E. Ahn, Stephan Stilgenbauer, Lydia Scarfo, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, John F. Seymour

Blood (2024) 144 (Supplement 1): 885.

https://doi.org/10.1182/blood-2024-199116

Published: 2024

Journal Articles

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Blood (2024) 144 (Supplement 1): 4610.

https://doi.org/10.1182/blood-2024-205727

Published: 2024

Journal Articles

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Alan P Skarbnik, Alexey V. Danilov, Marc Hoffmann, Farrukh T. Awan, Frank Scarpa, Caryn Davies, Todd Oakland, Marina Kovach, Jenna Lilyquist, Veerendra Munugalavadla, Alan SM Yong, Vikram Shetty, John N. Allan, Jennifer A. Woyach

Blood (2024) 144 (Supplement 1): 4623.

https://doi.org/10.1182/blood-2024-209590

Published: 2024

Journal Articles

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Jan A. Burger, Neil E. Kay, John N. Allan, Paul M Barr, Jacqueline C. Barrientos, Carolyn Owen, Victoria Wang, Hsin-Hui Huang, Lynne Neumayr, Christopher Abbazio, Gabriel S. Krigsfeld, Sneh Mody, Paolo Ghia, Tait D. Shanafelt

Blood (2024) 144 (Supplement 1): 4615.

https://doi.org/10.1182/blood-2024-194382

Published: 2024

Journal Articles

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

Theresia Akhlaghi, Jose Fernandez-Rengifo, Mateo Mejia Saldarriaga, Sarah C. Rutherford, Cara Rosenbaum, Jorge Monge, Peter Martin, John N. Allan, Richard R. Furman, Ruben Niesvizky, Mark Bustoros

Blood (2024) 144 (Supplement 1): 6350.

https://doi.org/10.1182/blood-2024-210059

Published: 2024

Journal Articles

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Jia Ruan, David A. Bond, Bijal D Shah, John N. Allan, Sarah C. Rutherford, Caitlin Gribbin, Zhengming Chen, Brittany Hobbie, Melinda Harbhajan, Tejasvi Sahni, Wayne Tam, Bhavneet Bhinder, Michael Sigouros, Giorgio Inghirami, Selina Chen-Kiang, Olivier Elemento, Kami J. Maddocks, John P. Leonard, Peter Martin

Blood (2024) 144 (Supplement 1): 746.

https://doi.org/10.1182/blood-2024-204495

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Matthew Matasar, Max S. Topp, John N. Allan, Stephen M. Ansell, Jeffrey A. Barnes, Jon E. Arnason, Jean-Marie Michot, Neta Goldschmidt, Susan M. O'Brien, Uri Abadi, Irit Avivi Mazza, Jingxian Cai, Julia Zecchini, Min Zhu, Jurriaan Brouwer-Visser, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, Jennifer L. Crombie

Blood (2024) 144 (Supplement 1): 866.

https://doi.org/10.1182/blood-2024-199155

Published: 2024

Journal Articles

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Tae Min Kim, Seok-Goo Cho, Michal Taszner, Geoffrey Chong, Jingxian Cai, Amulya Uppala, Aafia Chaudhry, Hesham Mohamed, Srikanth Ambati, John N. Allan

Blood (2024) 144 (Supplement 1): 862.

https://doi.org/10.1182/blood-2024-200190

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

John F. Seymour, Constantine S. Tam, Chan Y. Cheah, Ricardo D. Parrondo, John N. Allan, Judith Trotman, Ranjana H. Advani, Herbert A. Eradat, Pier Luigi Zinzani, Masa Lasica, Steven P. Treon, Xiangmei Chen, Kunthel By, Shannon Fabre, Daniel O. Persky, Amit Agarwal, Anna Maria Frustaci

Blood (2024) 144 (Supplement 1): 860.

https://doi.org/10.1182/blood-2024-199212

Published: 2024

Journal Articles

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

Blood (2024) 144 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2024-210134

Published: 2024

Journal Articles

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Blood (2024) 144 (Supplement 1): 3245.

https://doi.org/10.1182/blood-2024-205668

Published: 2024

Journal Articles

Consistently High 5.5-Year Progression-Free Survival (PFS) Rates in Patients with and without Bulky Baseline Lymphadenopathy ≥5 Cm Are Associated with High Undetectable Minimal Residual Disease (uMRD4) Rates after First-Line Treatment with Fixed-Duration Ibrutinib + Venetoclax for Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) in the Phase 2 CAPTIVATE Study

Blood (2024) 144 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2024-200936

Published: 2024

Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 2349.

https://doi.org/10.1182/blood-2024-203994

Published: 2024

Journal Articles

Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies

John N. Allan, Jennifer L. Crombie, Matthew Matasar, Max S. Topp, Jan Walewski, Tae Min Kim, Won-Seog Kim, Yuan Cheng, Dina Flink, Bertha Fearon Chalet, Hesham Mohamed, Srikanth Ambati, Aafia Chaudhry, Jon E. Arnason

Blood (2024) 144 (Supplement 1): 3118.

https://doi.org/10.1182/blood-2024-199980

Published: 2024

Journal Articles

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Kim Linton, John N. Allan, Andrew S Park, Anthony W Wang, Summer Tran, Alex Mutebi, Zhijie Ding, Quan Chen, Tycel J. Phillips

Blood (2024) 144 (Supplement 1): 1703.

https://doi.org/10.1182/blood-2024-200989

Published: 2024

Journal Articles

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

Blood (2024) 144 (Supplement 1): 5099.

https://doi.org/10.1182/blood-2024-198742

Published: 2024

Journal Articles

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

John N. Allan, Adam S Kittai, Dan James, Helen Ridge, Miguel Miranda, Alan Yong, Fady Fam, Jack Roos, Vikram Shetty, Matthew S. Davids, Alan Skarbnik

Blood (2023) 142 (Supplement 1): 6563.

https://doi.org/10.1182/blood-2023-178698

Published: 2023

Journal Articles

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

John N. Allan, Daniel Helbig, Erin Mulvey, Sarah Nazir, Sandra Stewart, Melissa L. Lapinta, Sarah C. Rutherford, Jia Ruan, John P. Leonard, Peter Martin, Richard R. Furman

Blood (2023) 142 (Supplement 1): 3285.

https://doi.org/10.1182/blood-2023-174465

Published: 2023

Journal Articles

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Matilde Micillo, Lorenzo Brandimarte, Giulia Omezzolli, Nadia Bertola, Francesco Edoardo Vallone, Andrea Iannello, Chiara Lavarello, Nicole Grinovero, Giulio Ferrero, Kevin Mellert, Peter Moller, Nicoletta Vitale, Silvia Bruno, Richard R. Furman, John N. Allan, Andrea Petretto, Silvia Deaglio, Silvia Ravera, Tiziana Vaisitti

Blood (2023) 142 (Supplement 1): 6115.

https://doi.org/10.1182/blood-2023-179164

Published: 2023

Journal Articles

Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data

John N. Allan, Tao Ran, Zhijie Ding, Jinghua He, Alex Bokun, Zaina P Qureshi, Susan M. O'Brien

Blood (2023) 142 (Supplement 1): 3278.

https://doi.org/10.1182/blood-2023-184318

Published: 2023

NARROW

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study

Topic Modeling of Genotyping of Transcriptomes Reveals Collaboration between BTK C481S -Mutant and Wild Type Cells in Btki-Resistant Chronic Lymphocytic Leukemia

Mutations in the Bruton Tyrosine Kinase ( BTK ) Gene in Patients with Chronic Lymphocytic Leukemia (CLL) Receiving BTK Inhibitors (BTKis)

Treatment with First-Line Ibrutinib Improves Overall Survival in Patients with Chronic Lymphocytic Leukemia (CLL) and High-Risk Genomic Features to Rates Approximating an Age-Matched US Population: Pooled Analysis of Phase 3 Trials with 10 Years of Follow-up

Disease Course and Risk Model Validation of Asymptomatic Waldenström Macroglobulinemia Patients - a Single Center Experience

MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA Analyses

Efficacy and Safety of Odronextamab Monotherapy in Patients (Pts) with Diffuse Large B-Cell Lymphoma (DLBCL) Progressing after CAR T-Cell Therapy: Primary Analysis from the ELM-1 Study

Efficacy and Safety of Odronextamab in Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL): Data from the R/R MZL Cohort in the ELM-2 Study

Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Waldenström Macroglobulinemia: Results from the Phase 1 CaDAnCe-101 Study

Enhancing Diagnostic and Prognostic Strategies in Secondary HLH: Insights from the Weill-Cornell Medicine Experience

A Multi-Center Retrospective Study on Complex Karyotype in Patients with Richter Transformation Who Received No Chemoimmunotherapy for Their CLL

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Long-Term Efficacy and Safety of Odronextamab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Pooled Analysis from the ELM-1 and ELM-2 Studies

Trends in All-Cause Mortality Rates in Patients with Follicular Lymphoma in the US before and during the COVID-19 Pandemic: A Retrospective Observational Study

Hodgkin Lymphoma Transformation in Patients Who Received No Prior Chemotherapy for CLL/SLL: Outcomes from a Multicenter Retrospective Study in the Modern Era of Therapy

A Matching-Adjusted Indirect Comparison of Acalabrutinib with and without Obinutuzumab Versus Zanubrutinib in Treatment-Naïve Chronic Lymphocytic Leukemia

Zanubrutinib and Venetoclax As Initial Therapy for CLL/SLL with Obinutuzumab Triplet Consolidation in Patients with Minimal Residual Disease Positivity (BruVenG)

The Characterization of Metabolic Profile and Substrates Dependencies of Richter's Syndrome Cells Open for Translational Opportunities

Overall Survival Outcomes in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Patients with High-Risk Molecular-Cytogenetic Features Treated with 1L Ibrutinib: A Comparative Effectiveness Study Using the Flatiron Health Data

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only